Vincentage Pharma
CompanyChina
Vincentage Pharma develops one asset, in phase 2 (VCT220 in obesity). Mostly small molecule acting on GLP1R; based in China.
- 1
- Asset
- Furthest stage
- Phase 2
- 3
- Trials
- 3
- Signals
Pipeline
1Activates GLP-1 receptors to enhance glucose-dependent insulin secretion and reduce appetite.
Phase 2, Small molecule, GLP1R, obesity, overweight
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials3
- Signals4
- Similar companies6